Quarterly ResultMay 12, 2026, 08:17 AM
Corbus Pharma Q1 Net Loss $23.0M; CRB-701 FDA Alignment, CRB-913 Enrollment Complete
AI Summary
Corbus Pharmaceuticals reported a net loss of $23.0 million for Q1 2026, an increase from $17.0 million in Q1 2025, with operating expenses rising to $24.3 million due to increased clinical development. Despite the financial loss, the company announced significant progress in its clinical programs, including broad FDA alignment for CRB-701's registration path in HNSCC and cervical cancer, with a registrational study expected to start this summer. Additionally, enrollment was completed for the CRB-913 CANYON-1 study for obesity, with topline data anticipated this summer.
Key Highlights
- Reached broad alignment with the FDA on the registration path for CRB-701 in HNSCC and cervical cancer.
- Anticipates initiating a registrational study for CRB-701 in second-line HNSCC this summer.
- Completed enrollment in the 240-patient CANYON-1 study for CRB-913 in obesity; topline data expected this summer.
- Reported Q1 2026 net loss of $23.0 million, compared to $17.0 million in Q1 2025.
- Operating expenses increased by $4.5 million to $24.3 million in Q1 2026, primarily due to clinical development.
- Held $138.2 million in cash, cash equivalents, and investments as of March 31, 2026.
- Cash runway expected to fund operations into 2028 based on current operating plans.